Exit
In order to receive credit for this activity, you must read the front matter, view the activity, achieve a passing of at least 100% on this post-survey, as well as complete the linked evaluation and application for credit form. Certificates of credit will be emailed to participants who have successfully met these requirements. 

There is no fee to participate in this activity.

Question Title

* 1. What are your specialty & credentials?

Question Title

* 2. What is your community of practice?

Question Title

* 3. What is the average number of patients you see per week with bladder cancer?

Question Title

* 4. How confident are you NOW in your knowledge of treatment of mUC in the first-line and maintenance setting?

Question Title

* 5. In the EV-302/KEYNOTE-A39 trial, enfortumab vedotin plus pembrolizumab reduced the risk of progression or death compared to chemo in previously untreated pts with mUC.

What was the hazard ratio noted in this study?

Question Title

* 6. Which of the following is considered a high-risk characteristic for a patient who is being assessed for potential treatment with enfortumab vedotin plus pembrolizumab?

Question Title

* 7. 65 year old patient with mUC
History of hypertension, diabetes, and Grade 2 peripheral neuropathy

According to the criteria developed by Gupta et al, are they eligible for platinum-based chemo?

Question Title

* 8. In the #JAVELINBladder100 trial, which ≥ Grade 3 TRAE occurred most often at any time during tx w/ avelumab?

EVALUATION FORM

Question Title

* 9. Upon completion of this activity, I am able to:

  Strongly agree Agree Disagree Strongly disagree
Describe efficacy data regarding ICIs and other approved drug classes, including the use of maintenance therapy in mUC.

Question Title

* 10. Please indicate the extent of your agreement with the following statements: 

  Strongly agree Agree Disagree Strongly disagree
The faculty for this activity were effective

Question Title

* 11. Overall, was this activity fair, balanced and free from commercial bias?

Question Title

* 12. If no, please explain:

Question Title

* 13. What percentage of activity content was new to you?

Question Title

* 14. Based on what I learned today, what changes do you plan to implement in your practice (check all that apply):

Question Title

* 15. Based on your experience, which of the following are the primary PATIENT-LEVEL barriers to implementing changes in practice in the 1L & maintenance settings of mUC (check all that apply):

Question Title

* 16. Based on your experience, which of the following are the primary PROVIDER-LEVEL barriers to implementing changes in practice in the 1L & maintenance settings of mUC (check all that apply):

Question Title

* 17. Based on your experience, which of the following are the SYSTEMS-LEVEL barriers to implementing changes in practicein the 1L & maintenance settings of mUC (check all that apply):

Question Title

* 18. For purposes of certification, please complete the following information. *Please note that we will not forward or sell your contact information.*

Question Title

* 19. I certify that I have participated in the continuing education activity entitled, "Tweetorial #1: First-Line and Maintenance Therapy for mUC" and claim 0.25 AMA PRA Category 1 CreditTM.

Thank you for participating in our activity and completing the necessary paperwork. Your certificate will be emailed to you using the email address provided above. Please allow 4 weeks to receive your certificate.

For additional information about the accreditation of this activity, please visit https://www.partnersed.com
( Privacy & Cookie Notice

T